Advertisement

Journal of Natural Medicines

, Volume 72, Issue 1, pp 274–279 | Cite as

Effects of saffron and its constituents, crocin-1, crocin-2, and crocetin on α-synuclein fibrils

  • Eiji InoueEmail author
  • Yasuharu Shimizu
  • Ryo Masui
  • Tomomi Hayakawa
  • Tomoe Tsubonoya
  • Satoko Hori
  • Keiichi Sudoh
Original Paper

Abstract

Saffron, the stigma of Crocus sativus Linné (Iridaceae family), has been known to inhibit aggregation of β-amyloid, a nerve tissue protein. α-Synuclein (αS) is a 140-amino acid protein found abundantly in various regions of the brain. Its abnormal aggregation and accumulation in nerve tissue are said to cause neurodegenerative diseases such as Parkinson’s disease, Lewy body dementia, and multiple-system atrophy. This study (part of this study was presented at the 137th Annual Meeting of the Pharmaceutical Society of Japan) examined the effects of saffron, its constituents (crocin-1, crocin-2, crocetin, and safranal), and crocetin structural analogs (hexadecanedioic acid, norbixin, and trans, trans-muconic acid) on αS aggregation, and αS fibril dissociation. Saffron dose-dependently inhibited αS aggregation and dissociated αS fibrils by thioflavin T fluorescence assay. These effects were observed by transmission electron microscopy, which showed reduced and shortened αS fibrils. Crocin-1, crocin-2, and crocetin showed anti-aggregation and fibril dissociation effects, with crocetin being the most potent. The effects of norbixin were weaker than those of crocetin, and the other crocetin structural analogs showed no effects. These results show that saffron and its constituents (crocin-1, crocin-2, and crocetin) can be effective in preventing and treating diseases caused by abnormal αS aggregation.

Keywords

Saffron α-Synuclein Crocin-1 Crocin-2 Crocetin 

Notes

Acknowledgements

TEM study was conducted at the University of Tokyo, supported by Nanotechnology Platform Program (Molecule and Material Synthesis) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.

Compliance with ethical standards

Conflict of interest

This research was supported by Kyushin Pharmaceutical Co., Ltd. The authors declare that there are no conflicts of interest.

References

  1. 1.
    Burré J (2015) The synaptic function of α-synuclein. J Parkinsons Dis 5:699–713CrossRefGoogle Scholar
  2. 2.
    Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501CrossRefGoogle Scholar
  3. 3.
    Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378–384CrossRefGoogle Scholar
  4. 4.
    Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s Diseases. PLoS ONE 3:e3135CrossRefGoogle Scholar
  5. 5.
    Ji K, Zhao Y, Yu T, Wang Z, Gong H, Yang X, Liu Y, Huang K (2016) Inhibition effects of tanshinone on the aggregation of α-synuclein. Food Funct 7:409–416CrossRefGoogle Scholar
  6. 6.
    Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, Safieh-Garabedian B, Al-Hayani AA, Eliezer D, Li M, El-Agnaf OM (2015) Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol Dis 74:89–101CrossRefGoogle Scholar
  7. 7.
    Ardah MT, Paleologou KE, Lv G, Abul Khair SB, Kazim AS, Minhas ST, Al-Tel TH, Al-Hayani AA, Haque ME, Eliezer D, El-Agnaf OM (2014) Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity. Front Aging Neurosci 6:197CrossRefGoogle Scholar
  8. 8.
    Namba T (1980) Colored illustrations of Wakan-Yaku Vol. II, Hoikusha, Osaka. pp 114–117Google Scholar
  9. 9.
    Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis P, Margarity M, Lamari FN (2006) Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 54:8762–8768CrossRefGoogle Scholar
  10. 10.
    Ahn JH, Hu Y, Hernandez M, Kim JR (2011) Crocetin inhibits beta-amyloid fibrillization and stabilizes beta-amyloid oligomers. Biochem Biophys Res Commun 414:79–83CrossRefGoogle Scholar
  11. 11.
    Ghahghaei A, Bathaie SZ, Kheirkhah H, Bahraminejad E (2013) The protective effect of crocin on the amyloid fibril formation of Aβ42 peptide in vitro. Cell Mol Biol Lett 18:328–339CrossRefGoogle Scholar
  12. 12.
    Karakani AM, Riazi G, Mahmood Ghaffari S, Ahmadian S, Mokhtari F, Jalili Firuzi M, Zahra Bathaie S (2015) Inhibitory effect of corcin on aggregation of 1N/4R human tau protein in vitro. Iran J Basic Med Sci 18:485–492PubMedPubMedCentralGoogle Scholar
  13. 13.
    Tong Y, Yan Y, Zhu X, Liu R, Gong F, Zhang L, Wang P (2015) Simultaneous quantification of crocetin esters and picrocrocin changes in Chinese saffron by high-performance liquid chromatography-diode array detector during 15 years of storage. Pharmacogn Mag 11:540–545CrossRefGoogle Scholar
  14. 14.
    Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, Safieh-Garabedian B, Al-Hayani AA, Eliezer D, Li M, El-Agnaf OM (2015) Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol Dis 74:89–101CrossRefGoogle Scholar
  15. 15.
    LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274–284CrossRefGoogle Scholar
  16. 16.
    Ono K, Yamada M (2007) Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases. Neurobiol Dis 25:446–454CrossRefGoogle Scholar
  17. 17.
    Asai A, Nakano T, Takahashi M, Nagao A (2005) Orally administered crocetin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice. J Agric Food Chem 53:7302–7306CrossRefGoogle Scholar
  18. 18.
    Yoshino F, Yoshida A, Umigai N, Kubo K, Lee MC (2011) Crocetin reduces the oxidative stress induced reactive oxygen species in the stroke-prone spontaneously hypertensive rats (SHRSPs) brain. J Clin Biochem Nutr 49:182–187CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer Japan KK 2017

Authors and Affiliations

  1. 1.Tokyo Research Center, Kyushin Pharmaceutical Co, Ltd.TokyoJapan

Personalised recommendations